SBC Medical Acquires Waqoo for Approximately JPY 1.09 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 2 hour ago0mins
- Acquisition Overview: SBC Medical is acquiring 575,052 common shares of Waqoo at JPY 1,900 per share for a total investment of approximately JPY 1.09 billion, which will make SBC Medical the parent company and largest shareholder of Waqoo, enhancing its influence in the Japanese market.
- Market Expansion Strategy: This acquisition not only boosts SBC Medical's R&D capabilities in regenerative medicine technologies but also significantly enhances its ability to deliver comprehensive solutions to medical organizations, thereby increasing its competitiveness in the global healthcare services market.
- Shareholding Structure Change: Following the acquisition, SBC Medical's voting rights are expected to exceed 50%, granting it a dominant position in Waqoo's decision-making processes and further solidifying its leadership in the healthcare sector.
- Future Outlook: This acquisition aligns with SBC Medical's strategic expansion plans and is expected to provide long-term growth opportunities, particularly in the healthcare technology sector in Japan, supporting its goals for global business expansion.
SBC.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on SBC
Wall Street analysts forecast SBC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBC is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.120
Low
9.00
Averages
9.00
High
9.00
Current: 4.120
Low
9.00
Averages
9.00
High
9.00
Maxim
Maxim
initiated
$9
2025-11-05
Reason
Maxim
Maxim
Price Target
$9
2025-11-05
initiated
Reason
Maxim initiated coverage of SBC Medical Group with a Buy rating and $9 price target.
See All Ratings
About SBC
SBC Medical Group Holdings Incorporated is a management company, which owns, operates, and provides management services to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including, but not limited to, advertising and marketing needs across various platforms, staff management, booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumable's procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program, and payment tools for the franchisee clinics.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?